Why the study?
Colchicine was recently approved by the US FDA for treating cardiovascular diseases, yet it is not yet used in Taiwan for conditions such as myocardial infarction, atherosclerosis, and ischemic stroke.
Does colchicine improve outcomes in patients with cardiovascular diseases?
Design
Narrative review
Key result
Colchicine has been recently approved by the US FDA for treating cardiovascular diseases, though its use requires careful medical supervision to minimize side effects.
Authors
Loading...
Demands careful supervision with FDA-approved colchicine in CV disease; leaves open optimal dosing and long-term outcomes.
Does colchicine improve outcomes in patients with cardiovascular diseases?
This narrative review highlights the recent FDA approval of colchicine for cardiovascular diseases and emphasizes the importance of medication safety and patient compliance.
Chen et al. (2026) conducted a review in cardiovascular diseases. Colchicine was evaluated. Colchicine has been recently approved by the US FDA for treating cardiovascular diseases, though its use requires careful medical supervision to minimize side effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: